Saturday 17 October 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
17.56
0.78
−4.25%
Follow DNLI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 16.11 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (49.67) | |
P/B ratio |
— | — | — | 5.77 | |
Price to Tangible BV |
— | — | — | 6.02 | |
EV/Sales |
— | — | — | 13.76 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (9.48) | |
EV/FCF |
— | — | — | (9.40) | |
Quick Ratio |
9.41 | 8.82 | 8.97 | 7.93 | |
Current Ratio |
9.79 | 9.16 | 9.28 | 8.37 | |
Net Debt/EBITDA |
6.17 | 6.33 | 7.23 | 5.49 | |
Debt/Assets |
0.53% | 0.48% | 0.44% | 0.47% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.26 | |
Operating CF/Net income |
0.85 | 0.77 | 1.02 | 0.76 | |
Capex/Depreciation |
1.50 | (1.25) | (1.55) | (0.38) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,691.98% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,006.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 635.82% | |
Graham Net Nets |
— | — | — | 0.09 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (11.04%) | |
Free Cash Flow Yield |
— | — | — | (9.08%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.02 | |
Operating CF per Share |
(0.62) | (0.57) | (0.70) | (0.52) | |
Capex per Share |
0.01 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.61) | (0.58) | (0.72) | (0.52) | |
Cash per Share |
4.92 | 5.03 | 5.29 | 3.79 | |
Shareholders Equity per Share |
5.37 | 5.87 | 4.96 | 4.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.37 | 5.87 | 4.96 | 4.46 | |
Free Cash Flow |
(105.92) | (100.06) | (133.67) | (97.81) | |
Working Capital |
792.45 | 802.31 | 912.60 | 663.84 | |
Capital Expenditures |
1.38 | (1.52) | (2.47) | (0.80) | |
Net Current Asset Value |
753.17 | 769.57 | 682.83 | 431.15 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.22 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 1.96 | |
Average Payables |
8.17 | 5.82 | 24.42 | 11.33 | |
Average Assets |
1,254.82 | 1,259.52 | 1,268.68 | 1,162.10 | |
Average Common Equity |
1,122.35 | 1,121.72 | 1,024.39 | 931.12 |
Columns are period end dates